VGFC yields 3883.50% · ABBV yields 3.12%● Live data
📍 VGFC pulled ahead of the other in Year 1
Combined, VGFC + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of VGFC + ABBV for your $10,000?
The Very Good Food Company Inc., together with its subsidiaries, designs, develops, produces, distributes, and sells various plant-based cheese, meats, and other food alternatives. The company offers its products through its wholesale and e-commerce stores, and public markets, as well as the Butcher Shop & Restaurant under The Very Good Butchers brand. The company provides plant-based cheese brands comprising Bold Cheddah, a white cheddar style vegan cheese; Cheedah, a medium cheddar style vegan cheese; Dill'ish, a garlic and dill-havarti style vegan cheese; Goud AF, a smoky gouda style vegan cheese; and Pepper Jack, a monterey jack style vegan cheese. It also offers plant-based meat products comprising a line of sausages, steaks, burgers, and meatballs that is gluten-free, soy-free, and Non-GMO verified under Butcher's Select and The Very Good Butchers brands. The company distributes and sells its products in 10 provinces and three territories in Canada and 50 states in the United States through eCommerce, wholesale, and company owned butcher shops and restaurants operated under Victoria Flagship Store name located in Victoria, Canada. The company was formerly known as The Very Good Butchers Inc. and changed its name to The Very Good Food Company Inc. in October 2019. The Very Good Food Company Inc. was incorporated in 2016 and is headquartered in Vancouver, Canada.
Full VGFC Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.